HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260)
South Korea
· Delayed Price · Currency is KRW 4,165.00
-10.00 (-0.24%)
At close: Mar 6, 2026
HYUNDAI BIOLAND Revenue
HYUNDAI BIOLAND had revenue of 35.48B KRW in the quarter ending September 30, 2025, with 10.96% growth. This brings the company's revenue in the last twelve months to 129.68B, up 15.99% year-over-year. In the year 2024, HYUNDAI BIOLAND had annual revenue of 119.52B with 23.57% growth.
Revenue (ttm)
129.68B
Revenue Growth
+15.99%
P/S Ratio
0.93
Revenue / Employee
380.29M
Employees
341
Market Cap
120.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.52B | 22.80B | 23.57% |
| Dec 31, 2023 | 96.72B | -2.43B | -2.45% |
| Dec 31, 2022 | 99.15B | -3.65B | -3.55% |
| Dec 31, 2021 | 102.80B | 13.90B | 15.64% |
| Dec 31, 2020 | 88.90B | -17.41B | -16.38% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PHARMARESEARCH BIO | 178.19M |
| WITHUS PHARMACEUTICAL Co.,LTD. | 102.11B |
| KOREA PHARMA | 90.11B |
| Samik Pharmaceutical Company LTD. | 58.88B |
| DongKoo Bio & Pharma | 238.39B |
| Kyung Dong Pharmaceutical | 193.64B |
| H.PIO | 257.56B |
| Sam-A Pharm. | 76.66B |